Pembrolizumab in RCC & Evolving Role of Immunotherapy in Metastatic RCC: ASCO 2018

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

Pembrolizumab in RCC & Evolving Role of Immunotherapy in Metastatic RCC: ASCO 2018

By Beacon Medical Interchange FEATURING Daniel Goldstein

168 views

November 2, 2018

Dr. Daniel Goldstein discusses the results of a trial of first line pembrolizumab (Keytruda) as ...
read more ↘ first line therapy for patients with metastatic clear cell renal cell carcinoma and the implications for the future role of immunotherapy in RCC.
↖ read less

0 Comments